Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma

被引:16
作者
Chen, Tingting [1 ]
Zhou, Lan [1 ]
Li, Hua [1 ]
Tian, Yuan [2 ]
Li, Junqin [1 ]
Dong, Lihua [1 ]
Zhao, Yuhua [1 ]
Wei, Dapeng [1 ]
机构
[1] Sichuan Univ, Dept Basic & Forens Med, 17,Sect 3,South Renmin Rd, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, West China Sch Med, Chengdu 610041, Sichuan, Peoples R China
关键词
epithelial-mesenchymal transition; fatty acid synthase; ErbB1-4; breast cancer; clinicopathological characteristics; GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASES; OVARIAN-CANCER; PROGNOSTIC-SIGNIFICANCE; SIGNALING PATHWAYS; MESSENGER-RNA; INACTIVE HER3; EGFR FAMILY; IN-VIVO; INHIBITOR;
D O I
10.3892/ol.2017.6954
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the present study was to investigate changes in the expression of ErbBs during epithelial-mesenchymal transition (EMT) of breast cancer cells and its association with the expression of fatty acid synthase (FASN). MCF-7-MEK5 cells were used as the experimental model, while MCF-7 cells were used as a control. Tumor cells were implanted into nude mice for in vivo analysis. Cerulenin was used as a FASN inhibitor. Reverse transcription-polymerase chain reaction and western blot analysis were used to detect expression levels of FASN and ErbB1-4. Immunohistochemistry was used to detect the expression of FASN and ErbB1-4 in 58 invasive ductal carcinomas (IDC), as well as their association with clinicopathological characteristics. The expression of FASN and ErbB1-4 in MCF-7-MEK5 cells and tumor tissues increased significantly compared with controls (P<0.001). Inhibition of FASN by cerulenin resulted in a significant decrease in expression of ErbB1, 2 and 4 (P<0.001), whereas there was no evident change in ErbB3. In IDC samples, the expression of FASN and ErbB1-4 increased considerably in lymph node metastases compared with non-lymph node metastases (P<0.05). ErbB2 expression increased in advanced clinical stages (II, III and IV) of IDC and in tumors with larger diameters (P<0.05). The expression of ErbB3 increased in ER-positive tumors (P<0.05). Additionally, a positive association between the expression of FASN and ErbB1, 2 and 4 was observed (P<0.05). FASN activates ErbB1, 2 and 4, and their dimers, which are polymerized via the microstructural domain of the cell membrane. This may initiate EMT and consequently increase the invasion and migration of cancer cells. However, ErbB3 may also affect tumor progression via a FASN-independent pathway.
引用
收藏
页码:5934 / 5946
页数:13
相关论文
共 78 条
[1]   Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma [J].
Abd El-Rehim, DM ;
Pinder, SE ;
Paish, CE ;
Bell, JA ;
Rampaul, RS ;
Blamey, RW ;
Robertson, JFR ;
Nicholson, RI ;
Ellis, IO .
BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1532-1542
[2]   c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems [J].
Allgayer, H ;
Babic, R ;
Gruetzner, KU ;
Tarabichi, A ;
Schildberg, FW ;
Heiss, MM .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (11) :2201-2209
[3]  
[Anonymous], 2011, CANC GENES CANC, DOI DOI 10.1177/1947601911431080
[4]   Role of tyrosine kinase inhibitors in cancer therapy [J].
Arora, A ;
Scholar, EM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979
[5]   Significance of epidermal growth factor receptor expression in breast cancer [J].
Badovinac-Crnjevic, Tanja ;
Jakic-Razumovic, Jasminka ;
Podolski, Paula ;
Plestina, Stjepko ;
Sarcevic, Bozena ;
Munjas, Radenka ;
Vrbanec, Damir .
MEDICAL ONCOLOGY, 2011, 28 :S121-S128
[6]   Elevated Coexpression of KITENIN and the ErbB4 CYT-2 Isoform Promotes the Transition from Colon Adenoma to Carcinoma Following APC loss [J].
Bae, Jeong A. ;
Kho, Dhong Hyo ;
Sun, Eun Gene ;
Ko, Yoo-Seung ;
Yoon, Somy ;
Lee, Kyung Hwa ;
Ahn, Kyu Youn ;
Lee, Jae Hyuk ;
Joo, Young Eun ;
Chung, Ik Joo ;
Lee, Sug Hyung ;
Kim, Hangun ;
Kim, Kyung Keun .
CLINICAL CANCER RESEARCH, 2016, 22 (05) :1284-1294
[7]   Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 [J].
Baselga, Jose ;
Swain, Sandra M. .
NATURE REVIEWS CANCER, 2009, 9 (07) :463-475
[8]   Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer [J].
Beji, Abdelhamid ;
Horst, David ;
Engel, Jutta ;
Kirchner, Thomas ;
Ullrich, Axel .
CLINICAL CANCER RESEARCH, 2012, 18 (04) :956-968
[9]  
Bruzzese F, 2011, J CELL PHYSIOL, V226, P2378, DOI 10.1002/jcp.22574
[10]   EGFR family: Structure physiology signalling and therapeutic targets [J].
Burgess, Antony W. .
GROWTH FACTORS, 2008, 26 (05) :263-274